Predictmedix AI Inc. (CSE:PMED, OTCQB:PMEDF) said results from a clinical validation conducted in collaboration with the University of Raharja in Indonesia have demonstrated 95% accuracy in vital sign detection.
The study focused on developing AI-based software with external support, capturing vital signs such as heart rate, respiration rate, height, body temperature, and blood pressure, non-invasively.
The company said the validation process involved a rigorous testing phase, scanning approximately 6,000 subjects, resulting in a remarkable 95% accuracy across critical parameters.
"The clinical validation with Raharja University is a pivotal milestone in fostering a 'Fit for Duty' culture. We envision safer and more efficient workplaces globally. The accuracy and maturity of our AI solution, especially in vital sign screening, are truly rewarding. We eagerly anticipate exploring broader applications to benefit society," Dr. Rahul Kushwah, chief operating officer of Predictmedix AI said in a statement.
The company noted that Raharja University endorses Predictmedix's Safe Entry Station solution.
It added that will be issue 50,000 common shares and 150,000 warrants with each warrant exercisable into a common share for 2 years at $0.10 per share, as consideration for the services provided by a consultant.